Journal article
Guidelines and Critical Pathways for Severe Hospital-Acquired Pneumonia
Chest, v 119(2), pp 412S-418S
Feb 2001
PMID: 11171778
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and adequate empiric therapy can increase the chance of survival. In 1995, the American Thoracic Society provided guidelines for the initial treatment of immunocompetent HAP patients, which is one of the principal HAP management approaches available to physicians today. However, these guidelines have several important limitations, including a lack of recommendations for duration of therapy and no recognition of newer drugs such as cefepime, trovafloxacin, and meropenem. Furthermore, they fail to distinguish among similar compounds (ie, β-lactam/β-lactamase inhibitor combinations) or to recommend specific antibiotics. The clinician using these guidelines needs to address local patterns of antimicrobial resistance, especially in ICUs. Effective computerized antibiotic management programs that incorporate information on local patterns of antimicrobial resistance can assist physicians in empiric therapy decision making, improve patient quality of care, and reduce medical costs.
Metrics
Details
- Title
- Guidelines and Critical Pathways for Severe Hospital-Acquired Pneumonia
- Creators
- Stanley Fiel - Drexel University
- Publication Details
- Chest, v 119(2), pp 412S-418S
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000167065100007
- Scopus ID
- 2-s2.0-0035110287
- Other Identifier
- 991019353719304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Critical Care Medicine
- Respiratory System